Palvella Therapeutics Upgrades Listing to Nasdaq Global Market

Palvella Therapeutics ( (PVLA) ) has provided an update.

On May 11, 2026, Palvella Therapeutics, Inc. announced that it had received approval from the Nasdaq Listing Qualifications Department to transfer its common stock listing from the Nasdaq Capital Market to the Nasdaq Global Market. The move, effective with the open of trading on May 13, 2026, keeps the PVLA ticker unchanged and positions the company on a higher-tier exchange segment, potentially enhancing its visibility and standing with investors and other market participants.

The most recent analyst rating on (PVLA) stock is a Buy with a $220.00 price target. To see the full list of analyst forecasts on Palvella Therapeutics stock, see the PVLA Stock Forecast page.

Spark’s Take on PVLA Stock

According to Spark, TipRanks’ AI Analyst, PVLA is a Neutral.

PVLA scores in the low-to-mid range primarily due to weak financial performance (widening losses and continued cash burn with no current revenue), partially offset by a low-debt balance sheet. Technical signals are neutral, while valuation lacks support due to negative earnings. The key positive swing factor is a strong set of recent corporate catalysts (positive Phase 3 data, progressing toward NDA, and substantial financing to fund commercialization readiness).

To see Spark’s full report on PVLA stock, click here.

More about Palvella Therapeutics

Palvella Therapeutics, Inc. is a biopharmaceutical company whose common stock trades under the ticker symbol PVLA on Nasdaq. The company operates in the life sciences sector, focusing on the development and commercialization of therapeutic products, and is publicly listed in the U.S. equity capital markets.

Average Trading Volume: 303,546

Technical Sentiment Signal: Buy

Current Market Cap: $1.8B

See more insights into PVLA stock on TipRanks’ Stock Analysis page.